The TheraBionic P1 device was approved by the FDA in September 2023 for the treatment of advanced liver cancer in adult patients for whom first- and second-line treatment therapies have failed, according to a Dec. 18 news release from the institute.
The portable device, co-invented by Karmanos President and CEO Boris Pasche, MD, PhD, targets liver cancer cell growth by delivering modulated radiofrequencies through a handheld antenna.
